Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

Atomwise and FutuRx Launch A2i Therapeutics – A New Immuno-Oncology Company Funded By Leading Biopharma VCs and the Israeli Innovation Authority

SAN FRANCISCO & NESS ZIONA, Israel–(BUSINESS WIRE/AETOSWire) – Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech innovation hub in Israel and is Atomwise’s second partnership with a global incubator hub. Founded through a joint investment between Johnson & Johnson Innovation (JJDC, Inc.), Takeda Ventures Inc., OrbiMed Israel Partners, FutuRx has formed over 20…

VentureIsrael Launches New Venture Capital Fund

VentureIsrael Launches New Venture Capital Fund

TEL AVIV, Israel–(BUSINESS WIRE/AETOSWire) – VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy. The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform. VentureIsrael is managed by five partners – all investment experts with diverse backgrounds: Michael Harte – former COO of Santander UK and…